Heart failure and transplantation with Dr Ileana Piña

 
 

Heart failure and transplantation with Dr Ileana Piña

  • AHA 2022 STRONG-HF Strategy for Intense ADHF Discharge Care Explained   Alexandre Mebazaa gives Ileana Piña the details on the STRONG-HF trial that showed benefits for early intensive drug therapy after hospitalization for acute decompensated heart failure.
  • AHA 2022 Meds and Community Over Mindfulness for Most Hypertension   Catch up on blood pressure presentations from the 2022 American Heart Association meeting, including ones on mindfulness, community approaches, and a comparison of hydrochlorothiazide and chlorthalidone.
  • ESC 2022 DELIVERing the Details on Dapagliflozin in Heart Failure   Drs Pina and Solomon discuss the DELIVER trial presented at the European Society of Cardiology and whether all patients with heart failure should get SGLT2 inhibitors regardless of ejection fraction.
  • The Pig Heart Transplant Surgeon on What He Learned   Ileana Piña speaks with Bart Griffith about the first porcine-to-human cardiac xenotransplantation and where the field is going.
  • Key Points From the New Heart Failure Guidelines   Dr Ileana Piña discusses the 2022 AHA/ACC/HFSA heart failure guidelines and how they compare with the European guidelines and recent data on heart failure.
  • ACC 2022 SODIUM-HF Simplifies Message to Patients on Diet   Drs Ileana Piña and Justin Ezekowitz discuss results from the SODIUM-HF trial, which investigated the effects of a pragmatic intervention to reduce dietary sodium intake in patients with heart failure.
  • Is It Time to Redefine Iron Deficiency?   Ileana Piña was intrigued by a paper questioning whether the definitions of iron deficiency used in HF trials and guidelines are the best ones.
  • AHA 2021 CHIEF-HF: No-Touch Initiation of Canagliflozin Improves QoL   Ileana Piña and Eldrin Lewis discuss a novel, all-virtual trial of the SGLT2 inhibitor canagliflozin in patients with heart failure.
  • ESC 2021 Heart Failure Drug Management Tips and Tricks   Drs Ileana Piña and Carolyn Lam discuss how they juggle all the drugs indicated for patients with heart failure.
  • ESC 2021 AVANTI: Could a 'Vaptan' Replace Loop Diuretics in Acute HF?   Ileana Piña and investigator James Udelson discuss the phase 2 AVANTI trial presented at ESC on a novel 'vaptan' drug.
  • ESC 2021 Empagliflozin in HFpEF: Putting EMPEROR-Preserved in Context   Javed Butler discusses the details of the trial on empagliflozin in HFpEF with Ileana Piña and what might be learned from the subgroup analyses.
  • ESC-HFA 2021 Can We Agree on a Universal Definition of Heart Failure?   Ileana Piña speaks with Professor Andrew Coats about the universal definition of heart failure and upcoming guidelines from the Heart Failure Association of the European Society of Cardiology.
  • ACC 2021 REHAB-HF Lays Groundwork for Recovery of Function Post HF   Ileana Pina speaks with Dalane Kitzman about a tailored strategy of physical rehabilitation to improve balance, strength, mobility, and endurance after acute HF.
  • ACC 2021 Sacubitril/Valsartan: Trending Toward PARADISE Post MI?   PARADISE-MI fell short on statistical significance but investigator Marc Pfeffer is persuaded by trends for clinical benefit. The key: 'Start the drug early and sustain it,' he tells Ileana Pina.
  • What to Know About New Hypertension Guidelines in CKD   Dr Ileana Piña asks Dr Peter A. McCullough what physicians need to know about heart failure and kidney disease, and the new hypertension guidelines in chronic kidney disease.
  • HFpEF: Do We Really Know What It Is?   Ileana Piña discusses phenotypes of patients with heart failure with preserved ejection fraction in the context of recent data from PARAGON-HF.
  • When the Patient Is the Best Practice Alert: EPIC-HF   Helping patients be proactive before their cardiology appointments can facilitate better management of HFrEF, says Larry Allen, lead author of EPIC-HF.
  • Hispanics and CVD: Country of Origin Matters   Hispanic, Latino -- the lingo and migratory patterns have changed over time, which is why clinicians should not assume that all patients share the same risk profiles, cautions Ileana Piña, MD.
  • ESC 2020 SGLT2 Inhibitors in HFrEF: Putting EMPEROR-Reduced in Context   Dr Ileana Piña asks the lead investigator how his trial on empagliflozin in HFrEF compares with DAPA-HF. They speculate on the likely mechanism of action of these relatively new drugs.
  • Cookbook Medicine Won't Cut It With New Drugs for HFrEF   The plethora of new drugs means one size will not fit all patients with HFrEF. Clinicians will have to tailor their strategies, says Ileana Pina, MD.